ArticleDiagnostic cytopathology2026
Turnaround Time Trends in Cervical Cytology Screening in South Africa, 2005-2023.
Article in Diagnostic cytopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTimely cervical cytology results are crucial for effective screening and early management of precancerous lesions. However, many low- and middle-income countries face delays in turnaround time (TAT). This study assessed TAT for cytology screening results in South Africa from 2005 to 2023 and identified factors associated with TAT delays.
methodsWe conducted a cross-sectional analysis of public health routine program data from the National Health Laboratory Service for women aged ≥ 15 years. We defined TAT as the time from sample collection to the release of results. The recommended TAT benchmark is 14 days; we defined delays as TAT exceeding 14 days. We used descriptive statistics and multivariable logistic regression to assess TAT trends and factors associated with delays.
resultsFrom 2005 to 2023, 12,246,041 cervical cytology smears were processed. The median age at screening was 38.8 years (IQR: 31.0-41.1), ranging from 15 to 95 years. Median TAT consistently exceeded 14 days, peaking at 25 days between 2014 and 2019. Delays were significantly associated with location, with higher odds in self-sufficient (aOR 2.33; 95% CI: 2.32-2.34) and laboratory-dependent regions (aOR 1.61; 95% CI: 1.61-1.62). Samples processed in referral laboratories had higher odds of delay (aOR 4.08; 95% CI: 4.07-4.10). Seasonal variation also affected TAT delays, with higher odds observed in the third quarter (aOR 1.40; 95% CI: 1.39-1.40) as compared to the first quarter.
conclusionThroughout South Africa, cervical cytology TAT remains above the recommended benchmarks. Delays are driven by structural and operational factors. Strengthening laboratory capacity, optimizing workflows, and transitioning to organized screening programs are critical for timely results and improved cervical cancer prevention outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.